Here is the design of a clinical trial:

Official Title: A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder

Included conditions:
- Suicidal Ideation
- Major Depressive Disorder

Study Armgroups:
- {'label': 'Sequential bilateral accelerated theta burst stimulation', 'type': 'ACTIVE_COMPARATOR', 'description': 'Three sessions of Sequential bilateral accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).', 'interventionNames': ['Device: MagVenture TMS Therapy System w/Theta Burst Stimulation']}
- {'label': 'Sham seqential billateral accelerated theta burst stimulation', 'type': 'SHAM_COMPARATOR', 'description': 'Three sessions of Sequential bilateral sham accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).', 'interventionNames': ['Device: Sham MagVenture TMS Therapy System w/Theta Burst Stimulation']}

Interventions:
- {'type': 'DEVICE', 'name': 'MagVenture TMS Therapy System w/Theta Burst Stimulation', 'description': 'During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.', 'armGroupLabels': ['Sequential bilateral accelerated theta burst stimulation'], 'otherNames': ['The MagVenture TMS Therapy System w/Theta Burst Stimulation']}
- {'type': 'DEVICE', 'name': 'Sham MagVenture TMS Therapy System w/Theta Burst Stimulation', 'description': 'During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.', 'armGroupLabels': ['Sham seqential billateral accelerated theta burst stimulation']}

Primary Outcomes:
- {'measure': 'Suicidal Ideation', 'description': 'Suicidal Ideation as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS). This is a validated, clinician-rated tool collected to assess lifetime and ongoing suicidal ideation and behavior. The severity of ideation subscale is a 5-point ordinal scale 1-5 . 1 = Wish to be dead - 5 = Active Suicidal Ideation with Specific Plan and Intent. Assessed at baseline, 10 days and 12 months.', 'timeFrame': 'up to 12 months'}
- {'measure': 'Hospitalizations', 'description': 'The total number of hospitalizations related to suicide idealization', 'timeFrame': 'up to 12 months'}

Please estimate the sample size based on the assumption: 
The sample size estimation and power analysis suggested that a sample size of 35 participants per group (N = 70) would achieve 80% power at a .05 significance level (2-tailed). The dropout rate is estimated to be 10%, based on previous repetitive TMS studies.
Sample size
        Based on prior experience, it is anticipated that 200 patients will be screened and 100 will be enrolled to reach the target sample size of 80 needed to complete this pilot study. The sample size for the primary outcome (suicidal ideation over 10 days of sequential bilateral aTBS treatment) was estimated by incorporating a repeated-measures design with assumptions about potential participants (eg, effect size, odds ratio [OR]). These assumptions were based on a 2018 study of the effect of bilateral repetitive TMS vs sham stimulation on suicidal ideation in adult patients with treatment-resistant MDD [31]. The results from the a priori sample size estimation and power analysis suggested that a sample size of 35 participants per group (N = 70) would achieve 80% power at a .05 Î± level (2-tailed) [31]. The aim is to detect an overall OR of 2.85 for the primary outcome of less suicidal ideation with sequential bilateral aTBS vs sham stimulation in a 2-group (between-participants) randomized design. The posited OR is based on 10 (within-participants) repeated measurements of severity of suicidal ideation on the CSSR-S subscale, when the proportion (incident rate) of suicidal ideation from the sham group at the end of the 10-day trial meets or exceeds 0.50 and the assumed within-participant correlation between observations (suicide ideation) for the same participant is 0.50 or less. (A correlation of 0.50 was based on guidance from our preliminary study of TMS [14].) The posited OR of 2.85 for the current application is slightly more conservative than what was reported in a study by Weissman et al [31] of effects of bilateral TMS vs sham stimulation on suicidal ideation in adult patients with treatment-resistant MDD (OR = 3.03).
        The dropout rate is estimated to be 10%, an approximation based on treatment discontinuation results from our previous repetitive TMS studies [14,80,81]. Thus, 80 participants will be enrolled to allow for this expected rate of attrition with the intent of capturing evaluable data for 70 participants. PASS (Power Analysis and Sample Size) 2019 software version 14.0.15 (NCSS) was used to perform the sample size and power analysis.
        To definitively evaluate the effect of sequential bilateral aTBS treatment on suicidal ideation in adolescents, we may require a sample size larger than 70. The treatment effect of sequential bilateral aTBS has not been previously studied in adolescents with suicidal depression, and we have no previous findings from an adolescent population to guide effect size selection for the present effort. The selection of 70 participants was, in part, resource driven. The sample size is designed to detect a moderate effect and to establish a proof of concept so that the research can expand to a subsequent, larger-scale multicenter study. Nevertheless, the current pilot study permits an evaluation of whether receiving sequential bilateral aTBS shows initial evidence of improving suicidal ideation in depressed adolescents.